Workflow
合同研发生产组织(CDMO)
icon
Search documents
大行评级|花旗:上调药明康德目标价至130港元 上调2025至27年盈测
Ge Long Hui A P P· 2025-07-30 03:56
Core Viewpoint - Citigroup reports that WuXi AppTec's management has raised its 2025 guidance primarily due to rapid capacity expansion rather than a surge in orders prior to the tariff war [1] Group 1: Revenue Guidance - Management expects that the revenue from continuing operations in the second half of 2025 will achieve double-digit growth both year-on-year and compared to the first half [1] - The new guidance indicates a year-on-year growth of 5% to 10% and a growth of 6% to 11% compared to the first half of 2025 [1] Group 2: Earnings Forecast - Citigroup did not significantly raise its revenue forecast for WuXi AppTec, as expectations were already adjusted following the first-quarter earnings announcement [1] - The bank has increased its earnings per share forecasts for WuXi AppTec for 2025 to 2027 by 3%, 6%, and 7% respectively, driven by margin expansion in the chemical business, a decrease in administrative expense ratios, and higher investment income [1] Group 3: Target Price Adjustment - Due to a more optimistic earnings outlook, Citigroup has raised the target price for WuXi AppTec's H-shares from HKD 95 to HKD 130 and for A-shares from CNY 88 to CNY 119 [1] - WuXi AppTec is now listed as a preferred stock in the Contract Development and Manufacturing Organization (CDMO) sector with a "Buy" rating [1]